May 24 - Dosimetry I and II and Radiobiology II

Radiopharmaceutical therapies (RPTs) are increasingly utilized for treatment of prostate, neuroendocrine, thyroid and other cancers. Radiation oncologists are experts regarding the benefits and risks associated with various cancer radiotherapeutic options and are thus uniquely positioned to evaluate radiation treatment options for patients, including the use of RPTs. Radiation oncologists are designated authorized users for RPTs, but do not frequently prescribe RPTs or pursue development of RPT programs due to lack of training, infrastructure and knowledge of how to establish a program. The lack of training may affect patient safety and access to care, especially for new therapeutic radiopharmaceuticals since few practitioners are actively developing the RPT programs in the country. This curriculum will address the training need.

Topics:

  • Dosimetry I – Dosimetry Methods and Individual Dose Planning, Uncertainties - Yuini Dewaraja, PhD
  • Dosimetry II / Radiobiology II – Bioeffect Modeling, Tumor Dose-Response, Toxicities, Alpha Emitters - Robert Francois Hobbs, PhD

Target Audience

This activity is designed to meet the interests of radiation oncologists, radiation physicists, radiation biologists and radiation oncology residents.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Appraise the pharmacokinetics (PK) and biodistribution of radioisotopes used in therapy.
  • Articulate the instrumentation, mathematics, and radiation protection measures necessary for the safe and effective use.
  • of radioactivity in RPT.
  • Articulate regulatory issues, standard operating procedures, and the process of becoming an authorized user in RPT, emphasizing quality assurance, patient-centered care, and safety protocols.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Certificate of Attendance
    This activity was designated for 2.00 AMA PRA Category 1 Credit™.
Course opens: 
03/28/2024
Course expires: 
07/04/2026
Cost:
$0.00
Rating: 
0
  • Yuni Dewaraja, PhD, is employed by University of Michigan Medicine. Dr. Dewaraja receives compensation from MIM Software and grant/research funding from GE Healthcare. 
  • Robert F. Hobbs, PhD, is employed by Johns Hopkins Medical Institute. Dr. Hobbs receives honoraria from Novartis/AAA and Varian. Dr. Hobbs receives compensation from Vivos. Dr. Hobbs owns the copyright for RAPID Dosimetry. Dr. Hobbs serves as Chair of the Radiopharmaceutical Therapy Subcommittee with AAPM.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Certificate of Attendance
    This activity was designated for 2.00 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.